1

Nawroz H et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996 Sep;2(9):1035-7.

2

Chen XQ et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996 Sep;2(9):1033-5.

3

Leon SA et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977 Mar;37(3):646-50.

4

Ziegler A et al. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev. 2002 Oct;28(5):255-71.

5

Lui YY et al. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med. 2002 Oct;40(10):962-8.

6

Lo YM et al. Noninvasive prenatal diagnosis: from dream to reality. Clin Chem. 2015 Jan;61(1):32-7.

7

Avent ND et al. Cell-free fetal DNA in the maternal serum and plasma: current and evolving applications. Curr Opin Obstet Gynecol. 2009 Apr;21(2):175-9. 

8

Puszyk WM et al. Noninvasive prenatal diagnosis of aneuploidy using cell-free nucleic acids in maternal blood: promises and unanswered questions. Prenat Diagn. 2008 Jan;28(1):1-6.

9

Lo YM et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997 Aug 16;350(9076):485-7.

10

Lo YM et al. Noninvasive prenatal detection of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis: a review of the current state of the art. BJOG. 2009 Jan;116(2):152-7. 

11

Dondorp W et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet. 2015 Nov;23(11):1592.

12

de Jong A et al. Non-invasive prenatal diagnosis for aneuploidy: toward an integral ethical assessment. Hum Reprod. 2011 Nov;26(11):2915-7.

13

Chiu RW et al. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat Diagn. 2012 Apr;32(4):401-6.

14

Metcalfe A et al. Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening. J Clin Med. 2014 Apr 8;3(2):388-415. 

15

Sifakis S et al. Noninvasive prenatal diagnosis of Down syndrome: current knowledge and novel insights. J Perinat Med. 2012 Feb 13;40(4):319-27.

16

Patterson D et al. Down syndrome and genetics - a case of linked histories. Nat Rev Genet. 2005 Feb;6(2):137-47.

17

Goodliffe JW et al. Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome. J Neurosci. 2016 Mar 9;36(10):2926-44. 

18

Vassy C et al. From a genetic innovation to mass health programmes: the diffusion of Down's Syndrome prenatal screening and diagnostic techniques in France. Soc Sci Med. 2006 Oct;63(8):2041-51. 

19

Chiang HH et al. Informed choice of pregnant women in prenatal screening tests for Down's syndrome. J Med Ethics. 2006 May;32(5):273-7.

20

Favre R et al. What about informed consent in first-trimester ultrasound screening for Down syndrome? Fetal Diagn Ther. 2008;23(3):173-84. 

21

Bianchi DW et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012 May;119(5):890-901. 

22

Chiu RW et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20458-63.

23

Bianchi DW et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014 Feb 27;370(9):799-808. 

24

Chiu RW et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011 Jan 11;342:c7401. 

25

Stumm M et al. Diagnostic accuracy of random massively parallel sequencing for non-invasive prenatal detection of common autosomal aneuploidies: a collaborative study in Europe. Prenat Diagn. 2014 Feb;34(2):185-91.

26

Tong YK et al. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin Chem. 2006 Dec;52(12):2194-202.

27

Walsh JM et al. Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment. Prenat Diagn. 2013 Jun;33(6):514-20.

28

Cheng SH et al. Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment. Clin Chem. 2015 Oct;61(10):1305-6. 

29

Dondorp W et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Summary and recommendations. Eur J Hum Genet. 2015 Apr 1.

30

Liang D et al. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn. 2013 May;33(5):409-15. 

31

Chitty LS et al. Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA. Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a023085. 

32

Wong FC et al. Prenatal Diagnosis Innovation: Genome Sequencing of Maternal Plasma. Annu Rev Med. 2016;67:419-32. 

33

Song Y et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn. 2013 Jul;33(7):700-6. 

34

Chitayat D et al. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can. 2011 Jul;33(7):736-50.

35

ACOG Committee on Practice Bulletins. et al. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007 Jan;109(1):217-27.

36

Tsui NB et al. Non-invasive prenatal detection of fetal trisomy 18 by RNA-SNP allelic ratio analysis using maternal plasma SERPINB2 mRNA: a feasibility study. Prenat Diagn. 2009 Nov;29(11):1031-7.

37

New MI et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab. 2014 Jun;99(6):E1022-30. 

38

Sun K et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5503-12

39

Wong AI et al. Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications. Trends Mol Med. 2015 Feb;21(2):98-108.

40

Benn PA et al. Maternal serum screening for birth defects: results of a Connecticut regional program. Conn Med. 1996 Jun;60(6):323-7.

41

Burton BK et al. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol. 1993 Sep;169(3):526-30.

42

Orlandi F et al. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol. 1997 Dec;10(6):381-6.

43

Spencer K et al. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn. 2000 Jun;20(6):491-4.

44

Stenhouse EJ et al. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn. 2004 Oct;24(10):774-80.

45

Spencer K et al. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG. 2000 Oct;107(10):1271-5.

46

Scott F et al. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Aust N Z J Obstet Gynaecol. 2004 Jun;44(3):205-9.

47

Alamillo CM et al. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn. 2013 Mar;33(3):251-6.

48

H?rmansd?rfer C et al. Age-independent first trimester screening for Down syndrome: analysis of three modified software programs with 6,508 pregnancies. Arch Gynecol Obstet. 2011 Apr;283(4):749-54. 

49

Kagan KO et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008 Sep;32(4):488-92.

50

Karadzov-Orlic N et al. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome. Prenat Diagn. 2012 Jul;32(7):638-43.

51

Marttala J et al. Screening and outcome of chromosomal abnormalities other than trisomy 21 in Northern Finland. Acta Obstet Gynecol Scand. 2011 Aug;90(8):885-9. 

52

Merz E et al. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med. 2008 Dec;29(6):639-45. 

53

Ranta JK et al. First trimester biochemistry at different maternal ages. Clin Chem Lab Med. 2011 Nov 24;50(3):549-55. 

54

Kazerouni NN et al. Triple-marker prenatal screening program for chromosomal defects. Obstet Gynecol. 2009 Jul;114(1):50-8.